Novo Nordisk’s latest deal with Valo Health aims to boost its cardiometabolic position - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Novo Nordisk will broaden its cardiometabolic pipeline by pairing up with machine learning and drug discovery startup Valo Health in a deal that builds on the Danish pharma's stature in the growing field. In exchange for $60 million upfront and in near-term p…